Catalyst Brief

← Calendar

Readoutin 14d

CanariaBio Inc. — Oregovomab

Phase 3 primary completion: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery.

Date
Dec 2026
Type
Readout
Indication
Carcinoma, Ovarian Epithelial

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.